In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rosetta Inpharmatics LLC

Division of Merck & Co. Inc.
www.rii.com

Latest From Rosetta Inpharmatics LLC

Novartis Follows Its Own Business Development Model into Molecular Diagnostics

Novartis is mirroring its approach to pharma R&D and leveraging the byproducts of its biomarker work there to build a commercial molecular diagnostics franchise. The head of the unit talks about its structure, strategy and programs.
Medical Device Strategy

A Friend-ly New Resource for Biomarker Validation?

Merck is helping one of its top executives launch a new nonprofit venture, called Sage, which will develop disease models and provide an open access platform for researchers to gauge the effects of perturbing them. Pharma has never really supported the diagnostics industry apart from its own internal need for biomarkers. But along with supporting drug development, Sage could actually go to that very kind of diagnostics development that pharma has not wanted to do in the past.
BioPharmaceutical

Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy

Merck's takeout of Sirna gives a boost to platform biotech investors and has allowed Merck to stake an expansive claim in RNAi. The deal caps a massive turnaround for Sirna--previously Ribozyme Pharmaceuticals--and rewards the investors who took an early chance on RNAi therapies. The move should pay off handsomely for Merck, now the leader in RNAi, provided the technology turns out to be the next Antibodies, not the next Antisense.
BioPharmaceutical Strategy

FoxHollow and Merck Expand Alliance, Aim at Vulnerable Plaque

What's the value of a well-documented set of clinical samples in the atherosclerosis business? For Merck, about $150 million. For FoxHollow, funding and validation for its contrarian device model.
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Merck & Co. Inc.
  • Senior Management
  • Peter Linsley, PhD, Exec. Dir., Research
    Stephen H Friend, MD, PhD, Pres.
  • Contact Info
  • Rosetta Inpharmatics LLC
    Phone: (206) 802-7000
    401 Terry Ave. N.
    Seattle, WA 98109
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register